
FibroBiologics Advances Innovative Cell Therapy: FDA Review of CYPS317 for Psoriasis Treatment Marks Major Clinical Milestone
FibroBiologics Inc, a clinical-stage biotechnology company, has announced a significant breakthrough in regenerative medicine by submitting a Phase 1/2 Investigational New Drug (IND) application to





















